COPD

Global Chronic Obstructive Pulmonary Disease Drugs Markets 2021-2025 - Strong Pipeline and New Drug Approvals & Growing Demand for Fixed-Dose Combinations - ResearchAndMarkets.com

Retrieved on: 
月曜日, 8月 30, 2021
Health, Pharmaceutical, Industry, CAGR, Smoking, Viatris, Merck, Research, Prevalence, Novartis, COPD, Chronic obstructive pulmonary disease, AstraZeneca, A.D. Bedell Wholesale Co., Inc. v. Philip Morris Inc., GlaxoSmithKline, Pharmaceutical industry

The "Global Chronic Obstructive Pulmonary Disease Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Obstructive Pulmonary Disease Drugs Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The chronic obstructive pulmonary disease drugs market is poised to grow by $5.63 bn during 2021-2025, progressing at a CAGR of 5.68%
    The market is driven by the rising prevalence of COPD, strong pipeline and new drug approvals, and the growing demand for fixed-dose combinations.
  • The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The chronic obstructive pulmonary disease drugs market analysis includes the product segment and geographic landscape.

Invacare’s Educational Program Receives International Accreditors for Continuing Education and Training (IACET) Designation

Retrieved on: 
月曜日, 8月 30, 2021
Education, Training, Health, Medical Devices, Industry, ALS, Program, Invacare, Muscular dystrophy, Corporation, Government, Accreditation, COPD, NYSE, IVC, Health, CEU, Chronic obstructive pulmonary disease, CEUS, Rancho Los Amigos National Rehabilitation Center, Rest, Spina bifida, Stroke, Cerebral palsy, Multiple sclerosis, Medicine

Invacare Corporation (NYSE: IVC) announced today that its well-established industry leading educational program received the International Accreditors for Continuing Education and Training (IACET) designation.

Key Points: 
  • Invacare Corporation (NYSE: IVC) announced today that its well-established industry leading educational program received the International Accreditors for Continuing Education and Training (IACET) designation.
  • Effective immediately, all courses which offer continuing educational units (CEU) from Invacare, Motion Concepts, Matrx, Alber and Pindot will carry IACET accreditation.
  • We are honored and excited to further expand our educational programs by offering accredited training to our providers and clinicians on a wide range of content.
  • The rigorous application process, which included extensive evaluation by the IACET Commission, took a year to complete and confirmed that Invacares educational curriculum is of the high quality.

Worldwide Chronic Obstructive Pulmonary Disease Industry to 2030 - Market Insights, Epidemiology and Forecasts - ResearchAndMarkets.com

Retrieved on: 
月曜日, 8月 30, 2021
Health, General Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Male, Population, SWOT, Research, Epidemiology, Female, Chronic obstructive pulmonary disease, Prevalence, COPD, MOA, Review, Report, III, USD, ROA, Vaccine, Dentistry, Health insurance, Coal, Pharmaceutical industry

The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The Chronic Obstructive Pulmonary Disease (COPD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Chronic Obstructive Pulmonary Disease (COPD) market size from 2018 to 2030.
  • The launch of emerging therapies will significantly impact the Chronic Obstructive Pulmonary Disease (COPD) market.

ZICOH® Technology by Vivera Granted Second U.S. Patent (US 11,090,449) for Smart Inhaler Device

Retrieved on: 
金曜日, 8月 27, 2021
Company, Epilepsy, Disease management, Neuroscience, Quality of life, Software, Administration, Parkinson's disease, Diabetes, Database, Chronic obstructive pulmonary disease, Degenerative disease, Prevalence, Patent, COPD, Asthma, Risk, United States Patent and Trademark Office, News, Patient, Compliance, CEO, FDA, Technology, Cystic fibrosis, USPTO, Pharmaceutical industry

NEWPORT BEACH, Calif., Aug. 27, 2021 /PRNewswire/ --The U.S. Patent and Trademark Office (USPTO) has granted Vivera's ZICOH technology a second U.S. Patent, No.

Key Points: 
  • NEWPORT BEACH, Calif., Aug. 27, 2021 /PRNewswire/ --The U.S. Patent and Trademark Office (USPTO) has granted Vivera's ZICOH technology a second U.S. Patent, No.
  • Vivera is pleased to announce ZICOH's second patent grant as it secures ZICOH's rights as a smart inhaler device featuring automated dose delivery, measurement, and management of medications.
  • At its core, ZICOH is a smart, secure, inhaler device featuring medication dosage control and delivery as part of a fully-integrated medication management system.
  • ZICOH is a secure, smart dosing device designed as part of a closed-loop medication management system backed by software and technology.

Invacare Corporation to Participate at September Conferences

Retrieved on: 
木曜日, 8月 26, 2021
Managed Care, General Health, Health, Medical Devices, Company, ALS, Morgan Stanley, Invacare, Muscular dystrophy, Corporation, Government, COPD, Treasury, NYSE, IVC, Health, Chronic obstructive pulmonary disease, Morgan, Rancho Los Amigos National Rehabilitation Center, Rest, Conference, Spina bifida, Stroke, Cerebral palsy, Multiple sclerosis, Medical device

Invacare Corporation (NYSE: IVC) a leading manufacturer and distributor of medical equipment used in non-acute care settings, announces its conference schedule for September 2021:

Key Points: 
  • Invacare Corporation (NYSE: IVC) a leading manufacturer and distributor of medical equipment used in non-acute care settings, announces its conference schedule for September 2021:
    Thursday, September 9, the Company will participate in the Morgan Stanley 19th Annual Global Healthcare Conference.
  • Tuesday, September 14, the Company will participate in the Baird 2021 Virtual Global Healthcare Conference.
  • Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings.
  • At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene.

NuvoAir Respiratory Platform Shows Promise for Long-Term Remote Monitoring of Asthma

Retrieved on: 
木曜日, 8月 26, 2021
ALS, University, Drug development, Muscular dystrophy, Self-management, Technology, Patient satisfaction, Conditional sentence, Royal Brompton Hospital, IPF, COPD, Asthma, Time, International Conference on Mechanical Industrial & Energy Engineering, Clinical trial, Patient, Spirometry, Conference, Bluetooth, American Thoracic Society, Cystic fibrosis, Pharmaceutical industry, Medical device, Tutoring

Patients also showed high adherence to home monitoring using the platform with impressive levels of satisfaction reported.

Key Points: 
  • Patients also showed high adherence to home monitoring using the platform with impressive levels of satisfaction reported.
  • A questionnaire was completed by 18 children with unstable asthma or their parents/carers regarding their experience and views on the NuvoAir platform.
  • Respondents rated home monitoring with the platform highly with 92.3% likely to continue using NuvoAir Home.
  • NuvoAir Home currently supports thousands of patients worldwide with COPD, asthma, cystic fibrosis, IPF, ALS, and muscular dystrophy.

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
木曜日, 8月 26, 2021
Health, Other Health, COPD: Journal of Chronic Obstructive Pulmonary Disease, Population, Male, Epidemiology, Female, Chronic obstructive pulmonary disease, Prevalence, COPD, Profile, United Kingdom, Signs and symptoms, GOLD, Vaccine, Dentistry, Medical imaging, Health insurance

The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast - 2030" drug pipeline report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology forecast - 2030" drug pipeline report has been added to ResearchAndMarkets.com's offering.
  • This 'Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Obstructive Pulmonary Disease (COPD) during the forecast period (2021-2030)?

Cigna Expands, Enhances ACA Marketplace Plans to Increase Access to Quality Care in More Communities

Retrieved on: 
木曜日, 8月 26, 2021
Government, Twitter, OEP, Growth, Open enrollment, Diabetes, HSA, Health, Provisions of the Affordable Care Act, COPD, Asthma, NYSE, Chronic obstructive pulmonary disease, Acupuncture, Patient, IL, Insulin, Facebook, IFP, Pharmacy, Express Scripts, Health insurance, Healthcare

Key features that Cigna IFP customers will enjoy include:

Key Points: 
  • Key features that Cigna IFP customers will enjoy include:
    Easy access to affordable care: $0 virtual wellness screenings with board-certified MDLIVE doctors via video, a convenient alternative to an in-person annual exam.
  • Our IFP growth in 2022 will enable Cigna to help more individuals and families access the care they need."
  • *Cigna provides access to dedicated virtual care through a national telehealth provider, MDLIVE located on myCigna, as part of your health plan.
  • Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health.

ResMed Announces SaaS Leadership Change

Retrieved on: 
水曜日, 8月 25, 2021
CTO, Quality of life, Growth, Software, Adoption, Digital, GLOBE, Conditional sentence, Sleep apnea, COPD, Software as a service, Farrell, NYSE, ResMed, ASX, Goal, SAN, Caregiver, RMD, Medicine

SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMeds SaaS business, effective immediately.

Key Points: 
  • SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), today announced the promotion of Bobby Ghoshal to President of ResMeds SaaS business, effective immediately.
  • Raj Sodhi will be leaving full-time employment at ResMed, effective September 1.
  • ResMed will commence a search process for a new CTO immediately; Bobby will remain in the CTO role until a replacement is found.
  • Id like to thank Raj for the incredible work hes done over the past nine years at ResMed, continued Farrell.

Arcutis Enrolls First Patient in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Scalp and Body Psoriasis

Retrieved on: 
水曜日, 8月 25, 2021
Company, Standard of care, Atopic dermatitis, Drug development, Quality of life, Twitter, Itchy, Pain, PDE4, Forehead, U.S. Securities and Exchange Commission, Joint Medical Service (Germany), Skin, GLOBE, SEC, Nasdaq, Disease, Food, Inflammation, Risk, COPD, NDA, Hair loss, Psoriasis, Chronic obstructive pulmonary disease, Silver, Dermatitis, Neck, Itch, Safety, Patient, LinkedIn, Hair, FAAD, Â, FDA, IGA, Dermatology, Form 10-K, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Petroleum jelly, Pharmaceutical industry

Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor, which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.

Key Points: 
  • Roflumilast foam is a once-daily topical foam formulation of roflumilast, a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor, which the Company is developing for both seborrheic dermatitis and scalp and body psoriasis.
  • In our previous Phase 2b trial, roflumilast foam was demonstrated to be a safe, well-tolerated, and effective potential treatment for scalp and body psoriasis.
  • Topical roflumilast foam is a once-daily, topical formulation of a highly potent and selective PDE4 inhibitor (roflumilast).
  • The companys lead product candidate, topical roflumilast, has the potential to advance the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.